300 related articles for article (PubMed ID: 30073392)
1. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
2. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
4. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
5. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
7. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
12. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
14. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
15. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Sohn SK; Moon JH
Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
[TBL] [Abstract][Full Text] [Related]
16. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?
Diamantopoulos PT; Viniou NA
Leuk Res; 2021 Apr; 103():106543. PubMed ID: 33640709
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
[TBL] [Abstract][Full Text] [Related]
20. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
